Fotograf: Herman Hamnqvist Till Verksamhetschef cc: Läkare och sjuksköterskor på arbetsplatsen cc: Berörd läkemedelskommitté Rolf Luft Symposium 2018 Rolf Luft Award Nobel Forum, Karolinska Institutet 30 maj 2018
Praktisk information Adress: Nobel Forum, KI Datum: Onsdag 30 maj 2018 Start: kl. 13.00 Slut: kl. 18.00 Inbjudna: Läkare, sjuksköterskor och andra med intresse för diabetes Symposium om diabetesvården (främst typ 2-diabetes) i Stockholm: Hur ser vårdens förutsättningar ut idag? Hur kan vårdens kvalité förbättras? Programkommitte: Michael Alvarsson Docent, Öl, Karolinska Universitetssjukhuset Solna Kerstin Brismar Professor, Karolinska Institutet Eva Hagström Toft Docent, Öl, Ersta sjukhus Thomas Nyström Professor, Öl, Södersjukhuset Mikael Rydén Professor, Öl, Karolinska Universitetssjukhuset Huddinge Joanna Uddén Hemmingsson Öl, Medicinkliniken Capio S:t Görans Sjukhus Ann-Sofie Bolmér Öl, Medicinkliniken Capio S:t Görans Sjukhus Lena Hallin-Landstedt Öl, Medicinkliniken Danderyds sjukhus David Nathanson Med. Dr. Öl, Karolinska Universitetssjukhuset Huddinge Claes-Göran Östenson Professor, Karolinska Institutet Annika Petersson Regional Market Access Manager, Novo Nordisk Johanna Andersson Regionalt Utbildningsansvarig Diabetes, Novo Nordisk Christina Östberg Lloyd CMR Director, Novo Nordisk Anmälan sker via www.fokusdip.se senast 23 Maj 2018 Kontaktpersoner Johanna Andersson Regionalt Utbildningsansv. Tel: 0706 38 89 74 Mail: jaxn@novonordisk.com Annika Petersson, Regional Market Access Manager Tel: 0702-411 784 Mail: apsn@novonordisk.com
Motivation for the Rolf Luft Award 2018 Professor Rudolf Zechner, Institute of Molecular Biosciences, Karl-Franzens-Universität Graz, Austria is awarded the 2018 Rolf Luft Award for his discovery of adipose triglyceride lipase and its role in intracellular catabolism of fat. After discovering adipose triglyceride lipase (ATGL) as the enzyme initiating fat catabolism in mammalian cells, Rudolf Zechner showed that comparative gene identification-58 (CGI-58) is an essential co-activator. These findings provided a molecular basis for understanding human neutral lipid storage diseases. He then revealed a crucial function for ATGL in lipid signaling by showing that the activity of the peroxisome proliferator-activated receptor (PPAR) family of transcription factors depends on ATGL-mediated fat catabolism. Further seminal discoveries connect ATGL to the pathogenesis of cancer cachexia and Zechner's work demonstrated that lipase deficiency inhibits the development of cachexia in mouse xenotransplant cancer models. His recent work elucidated the role of cardiac and brown adipose ATGL expression in cold-induced thermogenesis. Translational work by Zechner showed that the ATGL inhibitor Atglistatin reduces diet-induced obesity, improves glucose tolerance and prevents liver steatosis in mice, findings that identify ATGL as a target for treating metabolic diseases. Hence, Rudolf Zechner leads the field defining mechanisms for the intracellular catabolism of fat and his research has transformed textbook biochemistry, explained human genetic diseases and identified a promising strategy for treating metabolic disorders.
Program Rolf Luft Symposium Session 1 Rolf Luft Award Chair: Per-Olof Berggren, Professor Karolinska Institutet 13.00 Prize Ceremony Vice Chancellor Karin Dahlman-Wright Recipient of Rolf Luft Award 2018: Prof Rudolf Zechner, Graz, Österrike 14:00 Kaffepaus The Rolf Luft lecture FAT FISSION - The breakdown of cellular lipid stores in health and disease. Prof Rudolf Zechner, Graz, Österrike 14.30 Translational research from basic and applied science to clinical development Lars Fogh Iversen, Senior Vice President Global Research Technologies, Novo Nordisk Session 2 Rolf Luft Symposium: Typ 2-diabetesvården inom SLL: Hur ser den ut idag och hur kan den förbättras framgent? Chair: Claes-Göran Östenson, Professor Karolinska Institutet 14.50 Öppen- och slutenvården för typ 2-diabetes på sjukhusen inom SLL David Nathanson, Med. Dr. Öl, Karolinska Universitetssjukhuset Huddinge Ordf Svensk Förening för Diabetologi 15.05 Landstingets vision för diabetesvården inom SLL Barn- och äldrelandstingsråd i Stockholm Ella Bohlin, KD 15.20 Frågor/Diskussion David Nathanson/Ella Bohlin/Auditoriet 15.40 Vad betyder det nya Centrumet för Diabetes för diabetesvården? Sergiu Catrina, Medicinskt ansvarig för Centrum för Diabetes, ASC 15.55 Typ 2-diabetes i primärvården en utmaning Anna Ugarph-Morawski, Specialist i Allmän Medicin, Akademiskt Primärvårdscentrum 16.10 Evidensbaserad diabetesvård: Goda exempel från 4D-projektet i Jakobsberg och andra VC, Kaija Seijboldt, Diabetssjuksköterska, Akadmiskt Primärvårdscentrum 16.25 Frågor/Diskussion Sergiu-Bogdan Catrina/Anna Ugarph-Morawski/Kaija Seijboldt 16.35 Kort fruktpaus 16.50 Vad fattas diabetesvården inom SLL idag - och hur kan den förbättras? Anders Ekholm, ordf Storstockholms Diabetesförening 17.05 Triangelrevision av typ 2-diabetesvården - en metod för att förbättra vårdens kvalité, Claes-Göran Östenson, Professor Karolinska Institutet 17.20 Frågor/Diskussion 17.40 Avslutning och lättare förtäring
Rolf Luft Father of Endocrinology in Sweden He was born in 1914 in Stockholm, Sweden. In 1944, he obtained his PhD from Karolinska Institutet for his thesis entitled: A study on Hirsutism, Cushing s Syndrome and Precocious Puberty. A grant from the Knut & Alice Wallenberg Foundation in 1946 gave him the opportunity to visit Massachusetts General Hospital in USA for one year, working with Fuller Albright. As a professor and head of the Department of Endocrinology at Karolinska Hospital, he has supervised a legion of scholars in diabetes. He discovered in 1958 a disturbed function of mitochondria as a cause of disease (referred to as Luft disease) that led to the development of Mitochondrial Medicine for which the word identifies him as the Father of Mitochondrial Medicine. In the early descriptions of mitochondrial diseases, diabetes mellitus was thought to be related. In 1988, mutations in the mitochondria were associated with diabetes mellitus that led to the discovery of mitochondrial diabetes. He received innumerable awards, a number of honorary doctorates and was made an honorary member of several diabetic associations and scientific academies in different countries. He served as President of the International Diabetes Federation (IDF) for six years and was a founding member of The European Association for the Study of Diabetes (EASD). He was a member of the Nobel Assembly at Karolinska Institutet 1961 1980 and served as chairman of the Nobel Committee for Physiology or Medicine 1976-1978. Rolf Luft published the first national program for diabetes care 1967. Rolf Luft died in 2007.